Literature DB >> 26823692

Killing effect of TNF-mediated by conditionally replicating adenovirus on esophageal cancer and lung cancer cell lines.

Yue-Quan Jiang1, Zhi Zhang1, Hua-Rong Cai1, Hong Zhou1.   

Abstract

OBJECTIVE: The killing effect of TNF mediated by conditionally replicating adenovirus SG502 on human cancer cell lines was assessed by in vivo and in vitro experiments.
METHODS: The recombinant adenovirus SG502-TNF was used to infect human lung cancer cell line A549 and human esophageal cancer cell line TE-1. The expression of the exogenous gene and its inhibitory effect on the tumor cell lines were thus detected. Tumor transplantation experiment was performed in mice with the purpose of assessing the inhibitory effect of the adenovirus on tumor cells and tumor formation. The targeting of the adenovirus and the mechanism of tumor inhibition were discussed by in vivo imaging technology, HE staining and TUNEL assay.
RESULTS: Recombinant adenovirus SG502-TNF targeted the tumor cells specifically with stable expression of TNF, which produced a killing effect on tumor cells by regulating the apoptotic signaling pathway.
CONCLUSION: Recombinant adenovirus SG502-TNF possessed significant killing effect on TE-1 cells either in vivo or in vitro. This finding demonstrated the potential clinical application of adenovirus SG502.

Entities:  

Keywords:  Adenovirus; cancer cells; tumor necrosis factor

Mesh:

Substances:

Year:  2015        PMID: 26823692      PMCID: PMC4713478     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  18 in total

1.  Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells.

Authors:  R Rodriguez; E R Schuur; H Y Lim; G A Henderson; J W Simons; D R Henderson
Journal:  Cancer Res       Date:  1997-07-01       Impact factor: 12.701

2.  Tumor targeted adenovirus nanocomplex ionically crosslinked by chitosan.

Authors:  Yeonah Park; Eunah Kang; Oh-Jun Kwon; Hong-Kwan Park; Jung Hyun Kim; Chae-Ok Yun
Journal:  J Control Release       Date:  2010-11-20       Impact factor: 9.776

3.  Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.

Authors:  Xiong Li; Chaeyong Jung; You-Hong Liu; Kyung-Hee Bae; Yan-Ping Zhang; Hong-Ji Zhang; Dale Vanderputten; Meei-Huey Jeng; Thomas A Gardner; Chinghai Kao
Journal:  J Gene Med       Date:  2006-06       Impact factor: 4.565

4.  A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.

Authors:  Eric J Small; Michael A Carducci; James M Burke; Ron Rodriguez; Lawrence Fong; Lynn van Ummersen; D C Yu; Junko Aimi; Dale Ando; Peter Working; David Kirn; George Wilding
Journal:  Mol Ther       Date:  2006-05-09       Impact factor: 11.454

5.  Inhibition of the inflammatory cytokine TNF-α increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression.

Authors:  Michael A Salako; Hagen Kulbe; Carin K Ingemarsdotter; Katrina J Pirlo; Sarah L Williams; Michelle Lockley; Frances R Balkwill; Iain A McNeish
Journal:  Mol Ther       Date:  2010-11-16       Impact factor: 11.454

6.  A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer.

Authors:  T Ranki; A Kanerva; A Ristimäki; T Hakkarainen; M Särkioja; L Kangasniemi; M Raki; P Laakkonen; S Goodison; A Hemminki
Journal:  Gene Ther       Date:  2006-08-10       Impact factor: 5.250

7.  Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression.

Authors:  M Kuppuswamy; J F Spencer; K Doronin; A E Tollefson; W S M Wold; K Toth
Journal:  Gene Ther       Date:  2005-11       Impact factor: 5.250

8.  NF-κB targeting by way of IKK inhibition sensitizes lung cancer cells to adenovirus delivery of TRAIL.

Authors:  Cigdem Aydin; Ahter D Sanlioglu; Atil Bisgin; Burcak Yoldas; Levent Dertsiz; Bahri Karacay; Thomas S Griffith; Salih Sanlioglu
Journal:  BMC Cancer       Date:  2010-10-27       Impact factor: 4.430

9.  Systemic administration of a conditionally replicating adenovirus, targeted to angiogenesis, reduced lung metastases burden in cotton rats.

Authors:  Michael Peled; Aviv Shaish; Avi Katav; Shoshana Greenberger; Iris Barshack; Reshef Tal; Livnat Bangio; Eyal Breitbart; Dror Harats
Journal:  Clin Cancer Res       Date:  2009-02-24       Impact factor: 12.531

10.  Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses.

Authors:  Kilian Guse; Tuuli Ranki; Martti Ala-Opas; Petri Bono; Merja Särkioja; Maria Rajecki; Anna Kanerva; Tanja Hakkarainen; Akseli Hemminki
Journal:  Mol Cancer Ther       Date:  2007-10       Impact factor: 6.261

View more
  7 in total

1.  Tumor necrosis factor links chronic obstructive pulmonary disease and K-ras mutant lung cancer through induction of an immunosuppressive pro-tumor microenvironment.

Authors:  Lei Gong; Mauricio da Silva Caetano; Amber M Cumpian; Soudabeh Daliri; Alejandra Garza Flores; Seon Hee Chang; Cesar E Ochoa; Christopher M Evans; Zhentao Yu; Seyed Javad Moghaddam
Journal:  Oncoimmunology       Date:  2016-09-02       Impact factor: 8.110

Review 2.  Monitoring the Efficacy of Oncolytic Viruses via Gene Expression.

Authors:  Ashley Ansel; Joshua P Rosenzweig; Philip D Zisman; Beni Gesundheit
Journal:  Front Oncol       Date:  2017-11-06       Impact factor: 6.244

3.  Presence of complete murine viral genome sequences in patient-derived xenografts.

Authors:  Zihao Yuan; Xuejun Fan; Jay-Jiguang Zhu; Tong-Ming Fu; Jiaqian Wu; Hua Xu; Ningyan Zhang; Zhiqiang An; W Jim Zheng
Journal:  Nat Commun       Date:  2021-04-01       Impact factor: 14.919

Review 4.  Targeting the Blood-Brain Tumor Barrier with Tumor Necrosis Factor-α.

Authors:  Angelo Corti; Teresa Calimeri; Flavio Curnis; Andres J M Ferreri
Journal:  Pharmaceutics       Date:  2022-07-06       Impact factor: 6.525

5.  Study on the Changes and Significance of Immune State and Cycokines in Children with Adenovirus Pneumonia.

Authors:  Yue Hou; Jing Liu; Yanan Li; Fang Chen
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-02       Impact factor: 2.650

6.  The use of adenoviral vectors in gene therapy and vaccine approaches.

Authors:  Natália Meneses Araújo; Ileana Gabriela Sanchez Rubio; Nicholas Pietro Agulha Toneto; Mirian Galliote Morale; Rodrigo Esaki Tamura
Journal:  Genet Mol Biol       Date:  2022-10-07       Impact factor: 2.087

Review 7.  Oncolytic virotherapy in upper gastrointestinal tract cancers.

Authors:  Raquel Yokoda; Bolni M Nagalo; Mansi Arora; Jan B Egan; James M Bogenberger; Thomas T DeLeon; Yumei Zhou; Daniel H Ahn; Mitesh J Borad
Journal:  Oncolytic Virother       Date:  2018-03-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.